articles with this tag
One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market
Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking
Jul 25, 2019
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.
GTG Validates Cancer Tests As it Looks to Global Expansion
May 14, 2019
What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).
ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth
Apr 8, 2019
Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.
Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?
Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.
ASX Biotech Eyes International Distribution of Overlooked Cancer Drug
Oct 30, 2018
Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.